Barclays’s Zynerba Pharmaceuticals, Inc ZYNE Stock Holding History

Barclays’s Portfolio ZYNE Stock Details ZYNE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-1,000	Closed	-$5K	–	7387
2019 Q1	$5K	Buy	+1,000	New	+$4.87K	﹤0.01%	6727
2017 Q4	–	Sell	-500	Closed	-$4K	–	7183
2017 Q3	$4K	Buy	+500	New	+$5.29K	﹤0.01%	6528

Other funds holding ZYNE

EMG

ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PCM

Penserra Capital Management Orinda, California $8.52B AUM 37.76% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

Barclays's ZYNE Position: Q4 2021 in Review

Barclays sold out of Zynerba Pharmaceuticals, Inc (ZYNE) in Q4 2021, closing a stake of 7,268 shares — an estimated $31K sold.

Barclays first reported a position in ZYNE in Q2 2016 and held it in 20 quarters. The position peaked at $870K in Q2 2019. 62 funds tracked by Wall St. Rank hold ZYNE as of Q4 2021.

Barclays reported no remaining Zynerba Pharmaceuticals, Inc position as of Q4 2021 after selling out during the quarter.
Barclays sold 7,268 Zynerba Pharmaceuticals, Inc shares in Q4 2021, an estimated $31K.
Barclays first reported a position in Zynerba Pharmaceuticals, Inc in Q2 2016 and held it in 20 quarters.
Barclays's Zynerba Pharmaceuticals, Inc position peaked at $870K in Q2 2019.
62 funds tracked by Wall St. Rank held Zynerba Pharmaceuticals, Inc as of Q4 2021.

Based on Barclays's 13F filing for Q4 2021, filed 14 Feb 2022.